Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

6. Glycemic Targets: Standards of Medical Care in Diabetes—2022

Diabetes Care (2021) Vol. 45, Iss. Supplement_1, pp. S83-S96
Open Access | Times Cited: 602

Showing 1-25 of 602 citing articles:

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2753-2786
Open Access | Times Cited: 1145
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 1925-1966
Open Access | Times Cited: 670
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Circulation (2023) Vol. 148, Iss. 9
Open Access | Times Cited: 557
Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice
Moshe Phillip, Revital Nimri, Richard M. Bergenstal, et al.
Endocrine Reviews (2022) Vol. 44, Iss. 2, pp. 254-280
Open Access | Times Cited: 236
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Chengxu Ma, Xiaoni Ma, Conghui Guan, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 227
A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings
David C. Klonoff, Jing Wang, David Rodbard, et al.
Journal of Diabetes Science and Technology (2022) Vol. 17, Iss. 5, pp. 1226-1242
Open Access | Times Cited: 169
Cardiovascular Risk Factor Prevalence, Treatment, and Control in US Adults Aged 20 to 44 Years, 2009 to March 2020
Rahul Aggarwal, Robert W. Yeh, Karen E. Joynt Maddox, et al.
JAMA (2023) Vol. 329, Iss. 11, pp. 899-899
Open Access | Times Cited: 139
Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes
Eleanor L. Ramos, Colin Dayan, Lucienne Chatenoud, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 23, pp. 2151-2161
Closed Access | Times Cited: 97
Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus
David B. Sacks, Mark A. Arnold, George L. Bakris, et al.
Diabetes Care (2023) Vol. 46, Iss. 10, pp. e151-e199
Open Access | Times Cited: 83
The Influence of Lifestyle and Treatment on Oxidative Stress and Inflammation in Diabetes
Magdalena Wronka, Julia Krzemińska, Ewelina Młynarska, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 15743-15743
Open Access | Times Cited: 71
The importance of interpreting machine learning models for blood glucose prediction in diabetes: an analysis using SHAP
Francesco Prendin, Jacopo Pavan, Giacomo Cappon, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 50
Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus
David B. Sacks, Mark A. Arnold, George L. Bakris, et al.
Clinical Chemistry (2023) Vol. 69, Iss. 8, pp. 808-868
Open Access | Times Cited: 46
Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents
Jingqian Su, Yingsheng Luo, Shan Hu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13381-13381
Open Access | Times Cited: 45
Encapsulated stem cell–derived β cells exert glucose control in patients with type 1 diabetes
Bart Keymeulen, Kaat De Groot, Daniel Jacobs‐Tulleneers‐Thevissen, et al.
Nature Biotechnology (2023) Vol. 42, Iss. 10, pp. 1507-1514
Open Access | Times Cited: 45
The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes and a foot ulcer
Robert Fitridge, Vivienne Chuter, Joseph L. Mills, et al.
Diabetes/Metabolism Research and Reviews (2023) Vol. 40, Iss. 3
Open Access | Times Cited: 44
Impact of Preventive and Mandatory Social Isolation in the control of type I diabetes in adults in the Buenos Aires Metropolitan Area
Maria Isabel Morgner, Lorena Djament
Community and Interculturality in Dialogue (2023) Vol. 3, pp. 82-82
Open Access | Times Cited: 43
Advances in Continuous Glucose Monitoring and Integrated Devices for Management of Diabetes with Insulin-Based Therapy: Improvement in Glycemic Control
Jee Hee Yoo, Jae Hyeon Kim
Diabetes & Metabolism Journal (2023) Vol. 47, Iss. 1, pp. 27-41
Open Access | Times Cited: 41
Continuous glucose monitoring for the routine care of type 2 diabetes mellitus
Ramzi Ajjan, Tadej Battelino, Xavier Cos, et al.
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 7, pp. 426-440
Closed Access | Times Cited: 22
Real-World Evidence of Omnipod® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes
Gregory P. Forlenza, Daniel J. DeSalvo, Grazia Aleppo, et al.
Diabetes Technology & Therapeutics (2024) Vol. 26, Iss. 8, pp. 514-525
Open Access | Times Cited: 18
Development and Validation of a Machine Learning Model to Predict Weekly Risk of Hypoglycemia in Patients with Type 1 Diabetes Based on Continuous Glucose Monitoring
Simon Lebech Cichosz, Morten Hasselstrøm Jensen, Søren Schou Olesen
Diabetes Technology & Therapeutics (2024) Vol. 26, Iss. 7, pp. 457-466
Closed Access | Times Cited: 16
IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non‐insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trial
Ronnie Aronson, Ruth E. Brown, Lisa Chu, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 4, pp. 1024-1031
Open Access | Times Cited: 67
Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis
Wenting Xie, Fugui Su, Wang Gui-zhong, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 41
Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes Populations
Gregory P. Forlenza, Anders L. Carlson, Rodolfo J. Galindo, et al.
Diabetes Technology & Therapeutics (2022) Vol. 24, Iss. 11, pp. 814-823
Open Access | Times Cited: 40
Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes: From Injections to Hybrid Closed-Loop Therapy
Georgia M. Davis, Anne L. Peters, Bruce W. Bode, et al.
Diabetes Care (2023) Vol. 46, Iss. 4, pp. 742-750
Open Access | Times Cited: 38
Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial
Juliana Bue‐Valleskey, C Kazda, Chenchen Ma, et al.
Diabetes Care (2023) Vol. 46, Iss. 5, pp. 1060-1067
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top